Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors

1. A compound of the formula I:

wherein :

A is C 5-10 heterocyclyl;

B is a C 5-10 heterocyclyl selected from the group consisting of pyrimidinyl, naphthridinyl, pyrazinyl and pyridyl, wherein when B is pyrimidinyl it is presented by structural formula Ic:

wherein R 2a and R 2b in Ic are selected from the group consisting of hydrogen, halogen, and C 1-6 alkyl;

C is selected from the group consisting of (CH 2 ) n C 5-10 heterocyclyl, (CH 2 ) n O—C 5-10 heterocyclyi, C 2-6 alkenylC 5-10 heterocyclyl, C 3-10 cycloalkyl, and C 3-10 cycloalkenyl;

R 1a , R 1b and R 1c may be absent if the valency of A does not permit such substitution and are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) hydroxyl,

(4) C 1-6 alkyl, which alkyl is unsubstituted or substituted with halogen, hydroxyl, phenyl or napthyl,

(5) —O—C 1-6 alkyl, which alkyl is unsubstituted or substituted with halogen, hydroxyl or phenyl,

(6) phenyl, which is unsubstituted or substituted with 1 to 3 groups of R a ,

(7) C 5-10 heterocyclyl, which is unsubstituted or substituted with 1 to 3 groups of R a ,

(8) C 2-6 alkenylC 5-10 heterocyclyl, which heterocycle is unsubstituted or substituted with 1 to 3 groups of R a ,

(8) —O—phenyl, which is unsubstituted or substituted with 1 to 3 groups of R a ,

(9) C 3-10 ocycloalkyl which is unsubstituted or substituted with 1 to 3 groups of R a ,

(10) —NH—C 1-6 alkyl, or —N(C 1-6 alkyl)(C 1-6 alkyl), which alkyl is unsubstituted or substituted with 1 to 3 groups of R a ,

(11) —CO 2 H,

(12) —CN, and

(13) —NO 2 ;

R 2a , and R 2b may be absent if the valency of B does not permit such substitution, and R 2a , and R 2b and R 2c are independently selected from the group consisting of:

(1) hydrogen,

(2) halogen,

(3) hydroxyl,

(4) C 1-6 alkyl, which alkyl is unsubstituted or substituted with halogen, OR, phenyl or napthyl,

(5) —O—C 1-6 alkyl, which alkyl is unsubstituted or substituted with halogen, hydroxyl or phenyl,

(6) phenyl, which is unsubstituted or substituted with 1 to 3 groups of R a ,

(7) (CH 2 ) n heterocyclyl, which is unsubstituted or substituted with 1 to 3 groups of R a ,

(8) C 2-6 alkenylC 5-10 heterocyclyl, which is unsubstituted or substituted with 1 to 3 groups of R a ,

(9) (CH 2 ) n O—C 5-10 heterocyclyl, which is unsubstituted or substituted with 1 to 3 groups of R a ,

(10) C 3-10 ocycloalkyl which is unsubstituted or substituted with 1 to 3 groups of R a ,

(11) —O-phenyl, which is unsubstituted or substituted with halogen, hydroxyl, —O—C 1-6 alkyl or C 1-6 alkyl, which is unsubstituted or substituted with fluoro,

(12) —N(R) 2 , wherein when R is alkyl it is unsubstituted or substituted 1 to 3 groups of R a ,

(13) —CO 2 R,

(14) B(OH) 2 ;

(15) —CN,

(16) —NO 2 ,

(17) C(O)R, and

(18) C 2-6 alkenyl;

R is C 1-6 alkyl or hydrogen;

R a is selected from the group consisting of:

(1) hydroxyl,

(2) halogen,

(3) C 1-6 alkyl,

(4) —C 3-6 cycloalkyl,

(5) —O—C 1-6 alkyl,

(6) —O(C═O)—C 1-6 alkyl,

(7) C 1-6 alkylOH,

(8) (CH 2 ) n O C 1-6 alkyl

(8) —CO 2 H,

(9) —CO 2 -C 1-6 alkyl,

(10) —C(O)—C 1-6 alkyl,

(12) phenyl, which is unsubstituted or substituted with halogen, hydroxyl, —O—C 1-6 alkyl or C 1-6 alkyl, which is unsubstituted or substituted with fluoro,

(14) (CH 2 ) n heterocyclyl, which is unsubstituted or substituted with halogen, hydroxyl, —O—C 1-6 alkyl or C 1-6 alkyl, which is unsubstituted or substituted with fluoro,

(15) —CN, and

(16) N(R) 2

n is 0-4;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein A is selected from the group consisting of an optionally substituted pyridyl, cyclopentapyridinyl, dihydropyrrolopyrazolyl, pyrazolopyridinyl, thiazolyl, oxazolyl, pyrazolyl, quinolinyl, tetrahydronaphthyridinyl, and naphthyridine.

3. The compound of claim 1 wherein B is pyrimidinyl.

4. The compound according to claim 1 wherein R 1a , R 1b and R 1c are independently selected from hydrogen, hydrogen, C 1-6 alkyl, and —O—C 1-6 alkyl.

5. The compound according to claim 1 of formula I wherein R 2a , R 2b and R 2c are independently selected from the group consisting of hydrogen, halogen, hydroxyl, C(O)R, CN, N(R) 2 , pyrazolyl, C 1-6 alkyl, OC 1-6 alkyl, C 2-6 alkenyl, dimethylamino, dihydropyrrolopyrazolyl, thiazolyl, piperidinyl, pyrrolidinyl, ethenylpyridinyl, naphthyridinyl, C 1-6 alkylOH, (CH 2 ) n pyridyl, imidazopyrimidinyl, methoxypyridinyl, thiadiazolyl, cyclohexenyl, cyclopropyl, cyclohexyl, isoxaolyl, pyridinylethenyl, cyclopentenyl, pyrrolopyridinyl, imidazolyl, pyrazolopyridazine, triazolyl, triazolopyridinyl, and of formula Ic wherein R 2a and R 2b are selected from hydrogen and C 1-6 alkyl, all of which, where appropriate, may be optionally substituted with 1 to 3 groups of R a .

6. The compound according to claim 1 represented by structural formula Ia:

or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 represented by structural formula Ib:

or a pharmaceutically acceptable salt thereof.

8. The compound according to claim 1 represented by structural formula Id:

or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 represented by structural formula Ie:

or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 1 represented by structural formula If:

or a pharmaceutically acceptable salt thereof.

11. A compound which is selected from the group consisting of:

2-[4-(2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-1,5-naphthyridin-3-yl)-1H-pyrazol-1-yl]ethanol,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(1-methyl-1H-pyrazol-4-yl)pyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(1H-pyrazol-4-yl)pyrimidine, (2S)-2-[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl]propan-1-ol,

3-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-5,6-dihydro-4H-pyrrolo [1,2-b]pyrazole,

3-(2,4-dimethyl-1,3-thiazol-5-yl)-2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]-methoxy}-1,5-naphthyridine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(2-methyl-1,3-thiazol-5-yl)pyrimidine,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-3-(piperidin-3-yl)-1,5-naphthyridine, 1-[3-(2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-1,5-naphthyridin-3-yl)piperidin-1-yl]ethanone,

5-[(3,3-difluoropyrrolidin-1-yl)methyl]-4-{[(1S,2 S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-[(E)-2-(pyridin-3-yl)ethenyl]pyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-[(E)-2-(6-methylpyridin-3-yl)ethenyl]pyrimidine,

3-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-1,5-naphthyridine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(1-methyl-1H-pyrazol-4-yl)pyrimidine,

2-methoxy-4-{[(1,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-5-(1-methyl-1H-pyrazol-4-yl)pyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2,6-dimethyl-5-(1-methyl-1H-pyrazol-4-yl)pyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-[(pyridin-2-yloxy)methyl]pyrimidine,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-3-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridine,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-3-pyridin-3-yl-1,5-naphthyridine, 3-imidazo[1,2-a]pyrimidin-7-yl-2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-1,5-naphthyridine,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-3-(5-methyl-1,3,4-thiadiazol-2-yl)-1,5-naphthyridine,

2-[5-(2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-1,5-naphthyridin-3-yl)pyridin-2-yl]propan-2-ol,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-3-pyridin-4-yl-1,5-naphthyridine, 3-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-1,5-naphthyridine,

2-[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl]ethanol,

5-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-4-{[(1 S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-[1-(3-methylbutyl)-1H-pyrazol-4-yl]pyrimidine,

2-[5-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)pyridin-3-yl]propan-2-ol,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-pyridin-4-ylpyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-[1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl]pyrimidine,

1-[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl]-2-methylpropan-2-ol,

5-(2,4-dimethyl-1,3-thiazol-5-yl)-4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine,

4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)cyclohex-3-en-1-ol,

5-(3,5-dimethylisoxazol-4-yl)-4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-[(E)-2-pyridin-3-ylethenyl]pyrimidine,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-5,6-dimethyl-3-pyridin-3-ylpyrazine,

5-(3-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-5,6-dimethylpyrazin-2-yl)-1H-pyrrolo[2,3-b]pyridine,

2-(5-methoxypyridin-3-yl)-3-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-5,6-dimethylpyrazine,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-6-methyl-3-(3-methylisoxazol-4-yl)pyridine,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)pyridine,

3-(2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-5-methylpyridin-3-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole,

2-[4-(2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-5-methylpyridin-3-yl)-1H-pyrazol-1-yl]ethanol,

2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-3-pyridin-3-yl-1,7-naphthyridine,

2-[(1S,2S)-2-({[3-(1-methyl-1H-pyrazol-4-yl)-1,7-naphthyridin-2-yl]oxy}methyl)cyclopropyl]-1,5-naphthyridine,

2-methyl-5-(1-methyl-1H-pyrazol-4-yl)-4-{[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy}pyrimidine,

2-methyl-4-{[(1S,2S)-2-pyridin-2-ylcyclopropyl]methoxy}-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidine,

2-[(1S,2S)-2-({[2-methyl-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-yl]oxy}methyl)cyclopropyl]-1,5-naphthyridine,

2-[(1S,2S)-2-({[2-methyl-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-yl]oxy}methyl)cyclopropyl]quinoline,

6-[(1S,2S)-2-({[2-methyl-5-(1-methyl-1H-pyrazol-4-ly)pyrimidin-4-yl]oxy}methyl)cyclopropyl]-1,2,3,4-tetrahydro-1,5-naphthyridine,

2-[2-({[2-methyl-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-yl]oxy}methyl)-cyclopropyl]-6,7-dihydro-5H-cyclopenta[b]pyridine,

4-{[2-(3-fluoro-5-methylpyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidine,

2-[2-({[2-methyl-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidin-4-yl]oxy}methyl)-cyclopropyl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole,

2-[2-({[2-methyl-5-(1-methyl-1-pyrazol-4-yl)pyrimidin-4-yl]oxy}methyl)cyclopropyl]-pyrazolo[1,5-a]pyridine,

2-methyl-4-{[2-(2-methyl-1,3-thiazol-4-yl)cyclopropyl]methoxy}-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidine,

2-methyl-4-{[2-(2-methyl-1,3-oxazol-4-yl)cyclopropyl]methoxy}-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrimidine,

2-methyl-5-(1-methyl-1H-pyrazol-4-yl)-4-{[(1S,2S)-2-(1-methyl-1H-pyrazol-3-yl)cyclopropyl]methoxy}pyrimidine,

5-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine,

[2-cyclopropyl-5-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1,3-thiazol-4-yl]methanol,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(2-methyl-1,3-thiazol-4-yl)pyrimidine,

5-(1,2-dimethyl-1H-imidazol-5-yl)-4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]-methoxy}-2-methylpyrimidine,

2-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-3-methylimidazo[1,2-a]pyridine,

[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1-methyl-1H-pyrazol-3-yl]methanol,

4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1-methyl-1H-pyrazol-5-amine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(5-methyl-1-pyridin-3-yl-1H-pyrazol-4-yl)pyrimidine,

trans-4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)cyclohexanol,

cis-4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)cyclohexanol,

3-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-2-methylcyclopent-2-en-1-ol,

3-[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl]propan-1-ol,

3-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)pyrazolo [1,5-b]pyridazine,

5-(1,5-dimethyl-1H-pyrazol-4-yl)-4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine,

5-(1,3-dimethyl-1H-pyrazol-4-yl)-4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine,

2-[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-3,5-dimethyl-1H-pyrazol-1-yl]ethanol,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(1-methyl-1H-1,2,3-triazol-4-yl)pyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(2-methylpyridin-4-yl)pyrimidine,

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(6-methylpyridin-3-yl)pyrimidine,

7-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)[1,2,4]triazolo[1,5-a]pyridine,

6-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)[1,2,4]triazolo[1,5-a]pyridine,

6-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-N,N,2-trimethyl-5-(1-methyl-1H-pyrazol-4-yl)pyrimidin-4-amine,

1-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)pyrrolidin-3-ol,

2-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1,2,3,4-tetrahydro-2,6-naphthyridine,

or a pharmaceutically acceptable salt thereof.

12. The compound according to claim 11 which is:

2-[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl]ethanol

4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)cyclohex-3-en-1-ol

[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1-methyl-1H-pyrazol-3-yl]methanol

trans-4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)cyclohexanol

5-(1,3-dimethyl-1H-pyrazol-4-yl)-4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidine

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(6-methylpyridin-3-yl)pyrimidine

2-[4-(2-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-1,5-naphthyridin-3-yl)-1H-pyrazol-1-yl]ethanol

4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methyl-5-(1-methyl-1H-pyrazol-4-yl)pyrimidine

(2S)-2-[4-(4-{[(1S,2S)-2-(5-methoxypyridin-2-yl)cyclopropyl]methoxy}-2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl]propan-1-ol

or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.